Articles with public access mandates - William (Bill) BarryLearn more
Not available anywhere: 16
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
JF Liu, WT Barry, M Birrer, JM Lee, RJ Buckanovich, GF Fleming, ...
The Lancet Oncology 15 (11), 1207-1214, 2014
Mandates: US National Institutes of Health
Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer
SM Wong, RA Freedman, Y Sagara, F Aydogan, WT Barry, M Golshan
Annals of surgery 265 (3), 581-589, 2017
Mandates: US National Institutes of Health
Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial
SM Tolaney, N Tayob, C Dang, DA Yardley, SJ Isakoff, V Valero, ...
Journal of Clinical Oncology 39 (21), 2375-2385, 2021
Mandates: Susan G. Komen
Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy
RA Freedman, I Vaz-Luis, WT Barry, H Lii, NU Lin, EP Winer, NL Keating
Breast cancer research and treatment 145, 491-501, 2014
Mandates: US National Institutes of Health, Fundação para a Ciência e a Tecnologia …
Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis
A Di Meglio, RA Freedman, NU Lin, WT Barry, O Metzger-Filho, ...
Breast cancer research and treatment 157, 587-596, 2016
Mandates: Fundação para a Ciência e a Tecnologia, Portugal
Racial differences in outcomes for patients with metastatic breast cancer by disease subtype
I Vaz-Luis, NU Lin, NL Keating, WT Barry, H Lii, EP Winer, RA Freedman
Breast cancer research and treatment 151, 697-707, 2015
Mandates: US National Institutes of Health, Fundação para a Ciência e a Tecnologia …
Ribociclib plus trastuzumab in advanced HER2-positive breast cancer: results of a phase 1b/2 trial
S Goel, S Pernas, Z Tan-Wasielewski, WT Barry, A Bardia, R Rees, ...
Clinical Breast Cancer 19 (6), 399-404, 2019
Mandates: Government of Spain, Susan G. Komen
Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab
I Vaz-Luis, NU Lin, NL Keating, WT Barry, J Lii, HJ Burstein, EP Winer, ...
Breast cancer research and treatment 159, 151-162, 2016
Mandates: US National Institutes of Health, Fundação para a Ciência e a Tecnologia …
Phase II study of dasatinib in previously treated patients with advanced non-small cell lung cancer
MJ Kelley, G Jha, D Shoemaker, JE Herndon, L Gu, WT Barry, J Crawford, ...
Cancer investigation 35 (1), 32-35, 2017
Mandates: US Department of Veterans Affairs
Quantitative spectral reflectance imaging device for intraoperative breast tumor margin assessment
N Ramanujam, JQ Brown, TM Bydlon, SA Kennedy, LM Richards, ...
2009 Annual International Conference of the IEEE Engineering in Medicine and …, 2009
Mandates: US National Institutes of Health
Characterizing the clinical relevance of an embryonic stem cell phenotype in lung adenocarcinoma
M Stevenson, W Mostertz, C Acharya, W Kim, K Walters, W Barry, ...
Clinical Cancer Research 15 (24), 7553-7561 [Retraction: 2012;18(6):1818], 2009
Mandates: US National Institutes of Health
Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States
PD Poorvu, I Vaz-Luis, RA Freedman, NU Lin, WT Barry, EP Winer, ...
Breast cancer research and treatment 168, 727-737, 2018
Mandates: US National Institutes of Health, Fundação para a Ciência e a Tecnologia …
Bilateral mastectomy operations and the role for the cosurgeon technique: A Nationwide analysis of surgical practice patterns
MA Mallory, MG Valero, J Hu, WT Barry, K Losk, S Nimbkar, M Golshan
The Breast Journal 26 (2), 220-226, 2020
Mandates: US National Institutes of Health
Patterns of utilization of imaging studies and serum tumor markers among patients with de novo metastatic breast cancer
A Di Meglio, NU Lin, RA Freedman, WT Barry, EP Winer, I Vaz-Luis
Journal of the National Comprehensive Cancer Network 15 (3), 316-324, 2017
Mandates: US National Institutes of Health
The utility of magnetic resonance imaging in early‐stage breast cancer survivors—An institutional experience and literature review
T Sella, AA Dowton, ME Meyer, KJ Ruddy, ED Yeh, WT Barry, ...
The Breast Journal 26 (9), 1673-1679, 2020
Mandates: Susan G. Komen
Database Selection and Heterogeneity—More Details, More Credibility—Reply
R Barroso-Sousa, WT Barry, SM Tolaney
JAMA oncology 4 (9), 1295-1296, 2018
Mandates: National Natural Science Foundation of China
Available somewhere: 107
Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer
ML Telli, KM Timms, J Reid, B Hennessy, GB Mills, KC Jensen, Z Szallasi, ...
Clinical cancer research 22 (15), 3764-3773, 2016
Mandates: US National Institutes of Health, Susan G. Komen
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer
SM Tolaney, WT Barry, CT Dang, DA Yardley, B Moy, PK Marcom, ...
New England Journal of Medicine 372 (2), 134-141, 2015
Mandates: US National Institutes of Health
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
S Shu, CY Lin, HH He, RM Witwicki, DP Tabassum, JM Roberts, ...
Nature 529 (7586), 413-417, 2016
Mandates: US National Institutes of Health, Natural Sciences and Engineering Research …
Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus …
LA Carey, DA Berry, CT Cirrincione, WT Barry, BN Pitcher, LN Harris, ...
Journal of Clinical Oncology 34 (6), 542-549, 2016
Mandates: US National Institutes of Health, Susan G. Komen
Publication and funding information is determined automatically by a computer program